Posts

SVB Leerink Feedback on Editas Drugs, Inc.’s Q2 2022 Earnings (NASDAQ:EDIT)

SVB Leerink Feedback on Editas Drugs, Inc.’s Q2 2022 Earnings (NASDAQ:EDIT)

Editas Drugs, Inc. (NASDAQ:EDIT – Get Score) – SVB Leerink issued their Q2 2022 earnings per share estimates for shares of Editas Drugs in a report issued on Thursday, February twenty fourth. SVB Leerink analyst R. Bienkowski forecasts that the corporate will put up earnings of ($0.87) per share for the quarter. SVB Leerink has a “Market Carry out” score and a $27.00 value goal on the inventory. SVB Leerink additionally issued estimates for Editas Drugs’s Q3 2022 earnings at ($0.90) EPS and This fall 2022 earnings at ($0.85) EPS.

Editas Drugs (NASDAQ:EDIT – Get Score) final posted its quarterly earnings outcomes on Thursday, February twenty fourth. The corporate reported ($0.61) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.89) by $0.28. Editas Drugs had a unfavorable return on fairness of 31.42% and a unfavorable internet margin of 753.61%. The corporate had income of $12.50 million for the quarter, in comparison with analysts’ expectations of $4.70 million. Throughout the identical interval within the earlier yr, the agency earned ($1.00) EPS. The agency’s income was up 9.6% in comparison with the identical quarter final yr.

Different equities analysis analysts additionally not too long ago issued analysis experiences concerning the inventory. Barclays decreased their value goal on shares of Editas Drugs from $39.00 to $18.00 in a analysis observe on Friday. Zacks Funding Analysis raised shares of Editas Drugs from a “maintain” score to a “purchase” score and set a $20.00 value goal for the corporate in a report on Thursday, February third. Oppenheimer decreased their value goal on Editas Drugs from $80.00 to $55.00 and set an “outperform” score on the inventory in a analysis observe on Friday. Chardan Capital lowered their value goal on Editas Drugs from $75.00 to $60.00 and set a “purchase” score for the corporate in a analysis observe on Friday. Lastly, Evercore ISI lowered Editas Drugs to a “maintain” score and set a $15.00 value goal for the corporate. in a analysis observe on Friday, February eleventh. Two funding analysts have rated the inventory with a promote score, 5 have given a maintain score and 6 have given a purchase score to the corporate. Based mostly on knowledge from MarketBeat, Editas Drugs has a median score of “Maintain” and a median goal value of $38.58.

Read Also:  'Unhealthy medication, unhealthy coverage': Medical doctors blast rush to approve Omicron COVID vaccine with out human knowledge

NASDAQ EDIT opened at $17.12 on Monday. The inventory has a 50 day transferring common value of $20.98 and a 200-day transferring common value of $36.67. Editas Drugs has a one yr low of $13.25 and a one yr excessive of $73.03. The corporate has a market capitalization of $1.17 billion, a P/E ratio of -6.01 and a beta of two.03.

In associated information, CFO Michelle Robertson offered 1,744 shares of the agency’s inventory in a transaction that occurred on Tuesday, January eleventh. The inventory was offered at a median value of $25.70, for a complete transaction of $44,820.80. The sale was disclosed in a doc filed with the Securities & Trade Fee, which is offered by this hyperlink. 0.94% of the inventory is presently owned by firm insiders.

Numerous institutional buyers and hedge funds have not too long ago added to or decreased their stakes in EDIT. FMR LLC elevated its holdings in Editas Drugs by 143.2% through the 2nd quarter. FMR LLC now owns 52,017 shares of the corporate’s inventory price $2,946,000 after buying a further 30,631 shares through the interval. MML Traders Companies LLC bought a brand new place in Editas Drugs through the 2nd quarter price $339,000. Macquarie Group Ltd. elevated its holdings in Editas Drugs by 19.7% through the 2nd quarter. Macquarie Group Ltd. now owns 1,957 shares of the corporate’s inventory price $111,000 after buying a further 322 shares through the interval. Nuveen Asset Administration LLC elevated its holdings in Editas Drugs by 23.5% through the 2nd quarter. Nuveen Asset Administration LLC now owns 600,492 shares of the corporate’s inventory price $34,012,000 after buying a further 114,155 shares through the interval. Lastly, State Road Corp elevated its holdings in Editas Drugs by 9.1% through the 2nd quarter. State Road Corp now owns 2,534,162 shares of the corporate’s inventory price $143,535,000 after buying a further 210,444 shares through the interval. Institutional buyers personal 67.71% of the corporate’s inventory.

Read Also:  How Paul Farmer Modified Medication

About Editas Drugs (Get Score)

Editas Drugs, Inc engages within the improvement and commercialization of genome modifying know-how. Its know-how consists of clustered, frequently interspaced quick palindromic repeats (CRISPR), and CRISPR related protein 9 (Cas9). The corporate was based by Feng Zhang, Jennifer A. Doudna, George McDonald Church, J.

Learn Extra

Earnings History and Estimates for Editas Medicine (NASDAQ:EDIT)

Need Extra Nice Investing Concepts?

Obtain Information & Rankings for Editas Drugs Each day – Enter your electronic mail handle beneath to obtain a concise every day abstract of the most recent information and analysts’ rankings for Editas Drugs and associated corporations with MarketBeat.com’s FREE every day electronic mail e-newsletter.